

Neglected disease R&D investment


Anna Doubell

Director of Research, Policy Cures Research


Drug developments costs vs price



Drug R&D cost estimates




Policy Cures Research publications



Global funding for neglected disease drug R&D

Annual global funding of drug R&D

EUR m




Source: <https://gfinder.policycuresresearch.org/PublicSearchTool/>

Note: Adjusted for core funding to DNDi

€ 5.4 billion
10 years

19%
of all neglected disease
R&D funding

2007-2016 global funding of drug R&D, by disease



[^] Restricted category

* Other:


Cryptococcal meningitis EUR 18m

Salmonellosis EUR 16m

Buruli ulcer EUR 4.5m

Leprosy EUR 4.3m

Funders of neglected disease drug R&D, 2007-2016




Where does the money go?

Self-funding
39%
EUR 2,092m

External (grant) funding
61%
EUR 3,306m

Recipients of external funding, 2007-2016

- 87% industry
- 11% US government
- National S&T agencies



45%
€ 1.5 bn
of external
funding went
to PDPs

G-FINDER recap

- €5.4bn invested in neglected disease drug R&D over 10 years
- Mostly in malaria and TB
- Funded by industry, Gates Foundation, NIH and other HIC government funders
- R&D by industry, PDPs and universities


210 pipeline and registered drugs

Disease	Discovery	Pre-clinical	Phase I	Phase II	Phase III	Registered
Cryptococcal meningitis	-	1	-	-	-	-
Dengue	-	3	1	-	-	-
Diarrhoeal diseases	-	1	-	1	-	-
Helminth infections	1	2	1	-	2	1
Hepatitis C	-	-	-	1	1	1
HIV/AIDS	-	2	5	10	11	-
Kinetoplastids	10	4	2	2	1	3
Leprosy	-	1	-	-	-	-
Malaria	18	20	3	12	2	13
Tuberculosis	31	7	7	21	4	4
Total	60	41	19	47	21	22

Source: www.pipeline.policycuresresearch.org/august2017 and internal data

Note: Excludes HIV/AIDS microbicides

Who is involved?



210 pipeline and registered drugs

Archetype		Discovery	Pre-clinical	Phase I	Phase II	Phase III	Registered	Total
Repurposed drug	Simple	13	-	-	24	7	15	59
	Complex	1	9	5	-	-	-	15
New chemical entity	Simple	12	12	7	16	11	5	63
	Complex	32	17	7	6	2	2	66
Biologic	Simple	2	1	-	-	-	-	3
	Complex	-	2	-	1	1	-	4
Total		60	41	19	47	21	22	210

Source: www.pipeline.policycuresresearch.org/august2017

Note: Excludes HIV/AIDS microbicides

G-FINDER

- €5.4bn invested in neglected disease drug R&D over 10 years
- Mostly in malaria and TB
- R&D by industry, PDPs and universities

Pipeline

- 210 drugs in the pipeline or registered
- Mostly malaria and TB
- Collaboration between industry, PDPs and other

Conclusions

- Is neglected disease drug research cheaper?
- What are the drivers of difference?
- What are the lessons?

Thank you

Anna Doubell